Abstract
Netherton syndrome is a congenital skin disease associated with decreased skin barrier function and increased percutaneous absorption. We report an 11-year-old boy with Netherton syndrome who developed Cushing syndrome after application of 1% hydrocortisone ointment to his entire body for more than 1 year. This presentation illustrates that even low-potency steroid ointments should be used with caution in Netherton syndrome and warns about the use of long-term topical medications with potential systemic side effects when used in large quantities in any chronic skin disease.
MeSH terms
-
Administration, Cutaneous
-
Anti-Inflammatory Agents / poisoning*
-
Anti-Inflammatory Agents / therapeutic use
-
Child
-
Cushing Syndrome / chemically induced*
-
Humans
-
Hydrocortisone / poisoning*
-
Hydrocortisone / therapeutic use
-
Male
-
Mutation
-
Ointments
-
Proteinase Inhibitory Proteins, Secretory / genetics
-
Pruritus / drug therapy
-
Serine Peptidase Inhibitor Kazal-Type 5
-
Skin Absorption
-
Skin Diseases, Genetic / drug therapy*
-
Syndrome
Substances
-
Anti-Inflammatory Agents
-
Ointments
-
Proteinase Inhibitory Proteins, Secretory
-
SPINK5 protein, human
-
Serine Peptidase Inhibitor Kazal-Type 5
-
Hydrocortisone